Tucked away in page 93 of the prospectus after all the mind-numbing verbiage is the key fact that Covid testing boosted their profit figures that jumped by 24% in 2020 and which will recede fast in an year or two and return the valuation to around 3% return and a P/E of 35x. Right in time for Crescent Capital to cash in and leave the new mug investors to carry the can. The reputation of private equity for sharp dealing seems well deserved.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.77 |
Change
-0.035(1.25%) |
Mkt cap ! $544.0M | |||
| Open | High | Low | Value | Volume |
| $2.79 | $2.80 | $2.76 | $900.6K | 324.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 39814 | $2.76 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.77 | 11190 | 25 |
View Market Depth
| Last trade - 13.39pm 31/07/2025 (20 minute delay) ? |
| ACL (ASX) Chart |